Paliperidone extended-release: does it have a place in antipsychotic therapy?

Paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (PER), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gahr, Maximilian, Kölle, Markus A, Schönfeldt-Lecuona, Carlos, Lepping, Peter, Freudenmann, Roland W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063117/
https://www.ncbi.nlm.nih.gov/pubmed/21448450
http://dx.doi.org/10.2147/DDDT.S17266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063117/
https://www.ncbi.nlm.nih.gov/pubmed/21448450
http://dx.doi.org/10.2147/DDDT.S17266

Ejemplares similares